Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology

Cancer

Volumn 114, Issue 3, 2008, Pages 196-203

  Beccati, Maria Donatella ^a   Buriani, Carolina ^a   Pedriali, Massimo ^b   Rossi, Sonia ^b   Nenci, Italo ^b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Cervical cytology; Human papillomavirus carcinogenesis; MIB 1; Minichromosome maintenance protein 2; Squamous intraepithelial lesion; Topoisomerase IIa

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MOLECULAR MARKER; TOPOISOMERASE IIA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; COMPUTER ANALYSIS; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADULT; AGED; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 47049112761     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23496     Document Type: Article

References (20)

1. Bollmann R, Bankfalvi A, Bollmann M. Risk-adapted multimodal laboratory cervical screening - application of new technologies to cervical cancer prevention. Croat Med J. 2005;46:361-367.
2. Malinowski DP. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques. 2005;(suppl):17-23.
3. Padilla-Paz LA. Emerging technology in cervical cancer screening: status of molecular markers. Clin Obstet Gynecol. 2005;48:218-225.
4. Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van Diermen B, Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol. 2006;59:1017-1028.
5. Syrjanen KJ. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol. 2005;26:5-19.
6. Murphy N, Ring M, Heffron CC, et al. Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix Mod Pathol. 2005;18:844-849.
7. Murphy N, Ring M, Heffron CC, et al. p6INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58:525-534.
8. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta. 1998;1400(1-3):139-154.
9. Branca M, Giorgi C, Ciotti M, et al. Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol. 2006;25:383-392.
10. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291.
11. Ishimi Y, Okayasu I, Kato C, et al. Enhanced expression of Mem proteins in cancer cells derived from uterine cervix. Eur J Biochem. 2003;270:1089-1101.
12. Laskey R. The Croonian Lecture 2001 hunting the antisocial cancer cell: MCM proteins and their exploitation. Phil Trans R Soc London B Biol Sci. 2005;360:1119-1132.
13. Lei M, Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Scci. 2001;114 (pt 8): 1447-1454.
14. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation- associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513-522.
15. Kruse AJ, Gudlaugsson E, Helliesen T, et al. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk. Anal Quant Cytol Histol. 2004;26:134-140.
16. Kruse AJ, Baak JP, Janssen EA, et al. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol. 2003;199:462-470.
17. Kruse AJ, Baak JR de Bruin PC, van de Goot FR, Kurten N. Relationship between the presence of oncogenic HPV DNA assessed by polymerase chain reaction and Ki-67 immunoquantitative features in cervical intraepithelial neoplasia. J Pathol. 2001;195:557-562.
18. Kruse AJ, Baak JP, de Bruin PC, et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol. 2001;193:48-54.
19. Kelly D, Kincaid E, Fansler Z, Rosenthal DL, Clark DP. Detection of cervical high-grade squamous sintraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx™ C). Cancer. 2006;108:494-500.
20. Shroyer KR, Homer R Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer. 2006;108:324-330.